摘要
目的:探讨C-erbB-2蛋白及细胞角蛋白(CK19)在乳腺癌微转移中的表达及其临床意义。方法:我院2001年-2008年间手术切除的腋窝淋巴结阴性(ANN)乳腺癌石蜡标本60例淋巴结微转移(LNM),运用免疫组化SP法,进行C-erbB-2蛋白及腋窝淋巴结细胞角蛋白(CK19)检测,对相关资料进行回顾性分析,计算生存率并作单因素及多因素分析。结果:在ANN乳腺癌患者中,C-erbB-2的阳性表达与淋巴结微转移(LNM)密切相关,且C-erbB-2的表达强度与LNM率呈显著正相关。肿瘤大小(T)、组织分化程度与LNM率有显著相关,雌激素受体与LNM率无相关性。LNM与ANN乳腺癌患者的术后5年、10年无病生存率及死亡率有显著相关性。LNM阳性组其术后5年、10 无病生存率明显低于LNM阴性组,其术后死亡率明显高于LNM阴性组。结论:C-erbB-2的阳性表达可作为判断ANN乳腺癌预后的临床病理指标,C-erbB-2的较强表达,预示着腋窝淋巴结有微转移的倾向,对选择正确的治疗方案及判断预后,降低复发率具有极其重要意义。
Objective： To probe the expression of C-erbB-2 and CK19 in breast carcinoma micrometastasis and explore the clinical significance. Methods： The expression of C-erbB-2 and CK19 in the lymph nodes of 60 patients who underwent surgery for breast carcinoma were examined by immunohistochemical method, and all the paraffin samples had been pathologically proved without micrometastasis previously. The survival rate was measured, and the single and multi-factor analysis were performed. Results： In patients with axillary node-negative （ANN） breast carcinoma, the positive expression of C-erbB-2 was significantly correlated with the lymph node micrometastasis （LNM）. LNM rate was significantly related with tumor size and histodifferentiation degree, but not with the expression of estrogen receptors. LNM was a risk factor for 5 or 10-year disease-free survival rate and death rate of ANN breast carcinoma, and the 5 or 10-year disease-free survival rate was significantly lower in LNM positive group than that in negative group, but the death rate was significantly higher in LNM positive group. Conclusion： The positive expression of C-erbB-2 will become a elinicopathologic indicator in prognosis of breast carcinoma. Overexpression of C-erbB-2 implies the inclination of lymph node metastasis. It has a great value for selecting the surgery method, evaluating prognosis as well as reducing reoccurrence rate in breast carcinoma.
出处
《肿瘤预防与治疗》
2009年第3期246-249,349,共5页
Journal of Cancer Control And Treatment
